Alimera Sciences Inc (ALIM) 1.55 $ALIM
Alimera Sciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock
GlobeNewswire - Tue Aug 16, 3:01PM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has closed the previously announced underwritten public offering of 18,900,000 shares of its common stock at a price to the public of $1.40 per share for gross proceeds of $26.5 million. The shares include 900,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full.
ALIM: 1.55 (+0.02)
Alimera Sciences Prices Public Offering of Common Stock
GlobeNewswire - Thu Aug 11, 7:41AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $1.40 per share. In connection with the offering, Alimera has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price to cover over-allotments, if any. Gross proceeds from the sale of shares are expected to be approximately $25.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All shares in this offering are being sold by Alimera. This offering is expected to close on or about August 16, 2016 subject to customary closing conditions.
ALIM: 1.55 (+0.02)
Alimera Sciences Proposes Public Offering of Common Stock
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Alimera also expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price to cover over-allotments, if any. All of the shares in the offering are to be sold by Alimera, with net proceeds to be used to fund the continued commercialization of ILUVIENand for working capital and other general corporate purposes.
ALIM: 1.55 (+0.02)
Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting
GlobeNewswire - Tue Aug 09, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from three ILUVIEN post marketing studies will be presented during the American Society of Retinal Physicians (ASRS) 2016 Annual Meeting, August 10-14, in San Francisco. In addition, during the meeting Alimera will sponsor two symposia on the treatment of diabetic macular edema.
ALIM: 1.55 (+0.02)
Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Wed Aug 03, 4:41PM CDT
Strong revenue gains in the second quarter of 2016
ALIM: 1.55 (+0.02)
Alimera Sciences to Present at the LD Micro Invitational Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the LD Micro Invitational Conference, to be held June 7 - 9, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The Company's presentation will take place Wednesday, June 8, 2016 at 8:30 AM Pacific Time.
ALIM: 1.55 (+0.02)
Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien(R) At 12 Months
GlobeNewswire - Mon May 23, 3:00PM CDT
Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients
ALIM: 1.55 (+0.02)
Alimera Sciences to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 6:30AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the UBS Global Healthcare Conference, to be held May 23 - 25, 2016 at the The Grand Hyatt in New York City, New York. The Company's presentation will take place Monday, May 23, 2016 at 11:30 AM Eastern Time.
ALIM: 1.55 (+0.02)
Alimera Sciences' ILUVIEN(R) Data Presented at SFO 2016
GlobeNewswire - Wed May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10.
ALIM: 1.55 (+0.02)
Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO
PR Newswire - Fri May 06, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
ALIM: 1.55 (+0.02)
Alimera Sciences reports 1Q loss
Automated Insights - Wed May 04, 6:48PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $11.1 million in its first quarter.
ALIM: 1.55 (+0.02)
Alimera Sciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:23PM CDT
-- First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN(R) sales in the U.S.
ALIM: 1.55 (+0.02)
Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE - Wed Apr 27, 8:02AM CDT
DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM).
ALIM: 1.55 (+0.02), REGN: 393.40 (+0.85)
Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Tue Apr 26, 8:58AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
ALIM: 1.55 (+0.02)
New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 17.14 (+0.29), ALIM: 1.55 (+0.02), ARES: 18.92 (+0.64), AXTA: 28.95 (+0.33), ARNA: 1.56 (+0.01)
New Strong Sell Stocks for April 18th
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 6:42AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CRME: 2.92 (-0.06), ALIM: 1.55 (+0.02), CAR: 36.07 (-0.06), BAC: 15.98 (-0.16), CWT: 30.34 (-0.15)
New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 64.72 (+0.78), ALIM: 1.55 (+0.02), AMD: 7.35 (-0.05), CWT: 30.34 (-0.15), ATRS: 1.21 (-0.01)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016.
ALIM: 1.55 (+0.02), PSDV: 3.77 (-0.10), PVA: 0.15 (-0.04)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 52.97 (+0.16), FOMX: 8.67 (+0.37), GNST: (), GSK: 42.98 (-0.48), ALIM: 1.55 (+0.02), ALXN: 125.63 (-0.23), CBIO: 1.20 (unch), NVS: 78.27 (-0.50)
Alimera Sciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock
GlobeNewswire - Tue Aug 16, 3:01PM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has closed the previously announced underwritten public offering of 18,900,000 shares of its common stock at a price to the public of $1.40 per share for gross proceeds of $26.5 million. The shares include 900,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercised in full.
ALIM: 1.55 (+0.02)
Alimera Sciences Prices Public Offering of Common Stock
GlobeNewswire - Thu Aug 11, 7:41AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $1.40 per share. In connection with the offering, Alimera has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price to cover over-allotments, if any. Gross proceeds from the sale of shares are expected to be approximately $25.2 million, excluding any exercise of the underwriters' option to purchase additional shares. All shares in this offering are being sold by Alimera. This offering is expected to close on or about August 16, 2016 subject to customary closing conditions.
ALIM: 1.55 (+0.02)
Alimera Sciences Proposes Public Offering of Common Stock
GlobeNewswire - Wed Aug 10, 3:01PM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Alimera also expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price to cover over-allotments, if any. All of the shares in the offering are to be sold by Alimera, with net proceeds to be used to fund the continued commercialization of ILUVIENand for working capital and other general corporate purposes.
ALIM: 1.55 (+0.02)
Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting
GlobeNewswire - Tue Aug 09, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from three ILUVIEN post marketing studies will be presented during the American Society of Retinal Physicians (ASRS) 2016 Annual Meeting, August 10-14, in San Francisco. In addition, during the meeting Alimera will sponsor two symposia on the treatment of diabetic macular edema.
ALIM: 1.55 (+0.02)
Alimera Sciences Announces Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Wed Aug 03, 4:41PM CDT
Strong revenue gains in the second quarter of 2016
ALIM: 1.55 (+0.02)
Alimera Sciences to Present at the LD Micro Invitational Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the LD Micro Invitational Conference, to be held June 7 - 9, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The Company's presentation will take place Wednesday, June 8, 2016 at 8:30 AM Pacific Time.
ALIM: 1.55 (+0.02)
Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien(R) At 12 Months
GlobeNewswire - Mon May 23, 3:00PM CDT
Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients
ALIM: 1.55 (+0.02)
Alimera Sciences to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 6:30AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the UBS Global Healthcare Conference, to be held May 23 - 25, 2016 at the The Grand Hyatt in New York City, New York. The Company's presentation will take place Monday, May 23, 2016 at 11:30 AM Eastern Time.
ALIM: 1.55 (+0.02)
Alimera Sciences' ILUVIEN(R) Data Presented at SFO 2016
GlobeNewswire - Wed May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10.
ALIM: 1.55 (+0.02)
Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO
PR Newswire - Fri May 06, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
ALIM: 1.55 (+0.02)
Alimera Sciences reports 1Q loss
Automated Insights - Wed May 04, 6:48PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $11.1 million in its first quarter.
ALIM: 1.55 (+0.02)
Alimera Sciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:23PM CDT
-- First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN(R) sales in the U.S.
ALIM: 1.55 (+0.02)
Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE - Wed Apr 27, 8:02AM CDT
DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM).
ALIM: 1.55 (+0.02), REGN: 393.40 (+0.85)
Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Tue Apr 26, 8:58AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
ALIM: 1.55 (+0.02)
New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 17.14 (+0.29), ALIM: 1.55 (+0.02), ARES: 18.92 (+0.64), AXTA: 28.95 (+0.33), ARNA: 1.56 (+0.01)
New Strong Sell Stocks for April 18th
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 6:42AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CRME: 2.92 (-0.06), ALIM: 1.55 (+0.02), CAR: 36.07 (-0.06), BAC: 15.98 (-0.16), CWT: 30.34 (-0.15)
New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 64.72 (+0.78), ALIM: 1.55 (+0.02), AMD: 7.35 (-0.05), CWT: 30.34 (-0.15), ATRS: 1.21 (-0.01)
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9
GlobeNewswire - Thu Jan 28, 9:30AM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release drugs for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 18 Annual Bio CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, Monday and Tuesday, February 8 and 9. Dr. Ashton will make his presentation on Tuesday, February 9 at 11 a.m. EST. A webcast of the presentation will be available at the investor relations section of pSivida's website as well as this link: http://www.veracast.com/webcasts/bio/ceoinves...527117.cfm. A replay of the webcast will be available one hour after the conclusion of Dr. Ashton's presentation that day and will be available until May 8, 2016. ALIM: 1.55 (+0.02), PSDV: 3.77 (-0.10), PVA: 0.15 (-0.04)
Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 52.97 (+0.16), FOMX: 8.67 (+0.37), GNST: (), GSK: 42.98 (-0.48), ALIM: 1.55 (+0.02), ALXN: 125.63 (-0.23), CBIO: 1.20 (unch), NVS: 78.27 (-0.50)
